Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Lowered to $1,184.00 at Morgan Stanley

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price dropped by Morgan Stanley from $1,235.00 to $1,184.00 in a research report issued to clients and investors on Friday, Benzinga reports. The brokerage presently has an “overweight” rating on the biopharmaceutical company’s stock. Morgan Stanley’s price target indicates a potential upside of 40.35% from the company’s current price.

Other equities research analysts have also issued reports about the stock. StockNews.com raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. Cantor Fitzgerald reiterated a “neutral” rating and issued a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Barclays lowered their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday. JPMorgan Chase & Co. cut their target price on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Finally, BMO Capital Markets decreased their price target on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating for the company in a research report on Friday. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $1,090.24.

Regeneron Pharmaceuticals Stock Up 0.6 %

Shares of NASDAQ:REGN opened at $843.60 on Friday. Regeneron Pharmaceuticals has a 1 year low of $783.57 and a 1 year high of $1,211.20. The stock has a 50-day simple moving average of $1,058.43 and a 200-day simple moving average of $1,039.88. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.62 and a current ratio of 5.99. The stock has a market capitalization of $93.00 billion, a P/E ratio of 20.88, a PEG ratio of 2.88 and a beta of 0.15.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping the consensus estimate of $8.93 by $2.63. The company had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The company’s revenue was up 12.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $8.79 earnings per share. Equities analysts forecast that Regeneron Pharmaceuticals will post 37.46 earnings per share for the current year.

Insider Buying and Selling

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the transaction, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, CFO Christopher R. Fenimore sold 5,680 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the sale, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.48% of the stock is owned by company insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the stock. Stephens Consulting LLC bought a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $26,000. Sachetta LLC raised its stake in shares of Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares in the last quarter. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $28,000. Lynx Investment Advisory bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $33,000. Finally, Family Firm Inc. acquired a new position in Regeneron Pharmaceuticals during the second quarter worth about $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.